advanced search

Next Breath

Next Breath is a full-service cGMP-compliant laboratory specialising in analytical testing of a range of drug delivery systems, providing solutions from formulation and CMC support, to finished batch release and post-approval stability, to regulatory agencies worldwide.


Visit Website



Associated Companies

  Aptar Pharma     Aptar Digital Health     Gateway Analytical     Nanopharm     Noble  

Headquarters
Next Breath
Rolling Road
Baltimore
MD 21227
United States

Phone / Contact

T: +1 412 983 1634
E: [email protected]

Connect

Next Breath, a speciality company of Aptar Pharma, is a full-service cGMP-compliant laboratory specialising in analytical testing of a range of drug delivery systems, from early stage to commercialisation. Next Breath provides solutions for the product development process from formulation and CMC support, to finished batch release and post-approval stability, to regulatory agencies worldwide.

0

Articles by Next Breath

EXPERT VIEW
Dr Justin Lacombe
USING QUALITY BY DESIGN TO OPTIMISE THE COMBINATION PRODUCT JOURNEY
Justin Lacombe and Julie D Suman explain how applying quality by design principles to combination products improves development efficiency, aligns with design controls, and maximises product safety and efficacy.
NASAL
Dr Julie Suman
HOW EVOLVING PATIENT NEEDS HAVE FUELLED THE DEVELOPMENT OF NASAL DRUG DELIVERY
Julie Suman considers how the needs of the patient have driven advances in nasal drug delivery and looks at the latest developments and benefits of this method of drug delivery.
PULMONARY
Badre Hammond
GENERIC PMDI PRODUCT DEVELOPMENT FOR THE US: KEY CONSIDERATIONS
Badre Hammond highlights key considerations and addresses strategies that are believed to reduce risk and ultimately speed up the process for getting a generic pMDI product to the US market.
OCULAR
Badre Hammond
REDUCE RISKS, MITIGATE FAILURE & DRIVE TIMELINES IN A COMPETITIVE MARKET
Badre Hammond, Shailuja Somaraju and Julie Suman highlight key considerations and present strategies to reduce risk and ultimately accelerate the process for gaining approval of an ophthalmic product, with a focus on the US.
Top